CONCENTRATIONS OF PRAVASTATIN AND LOVASTATIN IN CEREBROSPINAL-FLUID IN HEALTHY-SUBJECTS

被引：116

作者：

BOTTI, RE

TRISCARI, J

PAN, HY

ZAYAT, J

机构：

[1] BRISTOL MYERS SQUIBB CO,BRISTOL MYERS SQUIBB PHARMACEUT RES INST,CARDIOVASC RES,POB 4000,PRINCETON,NJ 08543

[2] PHARMACEUTICAL RES CORP OHIO INC,CLEVELAND,OH

[3] CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106

[4] MERIDIA HURON HOSP,DEPT MED,CLEVELAND,OH

来源：

CLINICAL NEUROPHARMACOLOGY | 1991年 / 14卷 / 03期

关键词：

PRAVASTATIN; LOVASTATIN; CEREBROSPINAL FLUID (CSF); BLOOD-BRAIN BARRIER;

D O I：

10.1097/00002826-199106000-00010

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The capability of pravastatin and lovastatin, HMG-CoA reductase inhibitors likely to be taken chronically for hypercholesterolemia, to cross the blood-brain barrier was investigated in normal male volunteers. Lovastatin, which is lipophilic, was detected in cerebrospinal fluid (CSF) at concentrations that may have a pharmacologic effect. Pravastatin, which is hydrophilic, was not detected in CSF. It is concluded that pravastatin may have less potential for causing CNS-related side effects than lovastatin.

引用

页码：256 / 261

页数：6

共 22 条

[1] MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT [J].

ALBERTS, AW ;

CHEN, J ;

KURON, G ;

HUNT, V ;

HUFF, J ;

HOFFMAN, C ;

ROTHROCK, J ;

LOPEZ, M ;

JOSHUA, H ;

HARRIS, E ;

PATCHETT, A ;

MONAGHAN, R ;

CURRIE, S ;

STAPLEY, E ;

ALBERSSCHONBERG, G ;

HENSENS, O ;

HIRSHFIELD, J ;

HOOGSTEEN, K ;

LIESCH, J ;

SPRINGER, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07) :3957-3961

[2] PRELIMINARY-RESULTS OF A DOUBLE-BLIND COMPARISON OF PRAVASTATIN AND CHOLESTYRAMINE IN FAMILIAL HYPERCHOLESTEROLEMIA [J].

BETTERIDGE, J ;

BHATNAGAR, D ;

DURRINGTON, P ;

EVANS, G ;

JAY, R ;

LEWISBARNED, N ;

MANN, J ;

MATSAKIS, M ;

MATTHEWS, D ;

MILLER, P ;

RECKLESS, J ;

STURLEY, R ;

TAYLOR, K ;

WINDER, A .

ATHEROSCLEROSIS, 1989, 79 (01) :96-96

[3] VARIATIONS OF MEMBRANE CHOLESTEROL ALTER THE KINETICS OF CA-2+-DEPENDENT K+ CHANNELS AND MEMBRANE FLUIDITY IN VASCULAR SMOOTH-MUSCLE CELLS [J].

BOLOTINA, V ;

OMELYANENKO, V ;

HEYES, B ;

RYAN, U ;

BREGESTOVSKI, P .

PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1989, 415 (03) :262-268

[4]

DUGGAN DE, 1989, DRUG METAB DISPOS, V17, P166

[5] LOVASTATIN AND OTHER HMG-COA REDUCTASE INHIBITORS [J].

FRISHMAN, WH ;

ZIMETBAUM, P ;

NADELMANN, J .

JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 29 (11) :975-982

[6] DETERMINATION OF PRAVASTATIN SODIUM AND ITS MAJOR METABOLITES IN HUMAN-SERUM PLASMA BY CAPILLARY GAS-CHROMATOGRAPHY NEGATIVE-ION CHEMICAL IONIZATION MASS-SPECTROMETRY [J].

FUNKE, PT ;

IVASHKIV, E ;

ARNOLD, ME ;

COHEN, AI .

BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, 1989, 18 (10) :904-909

[7] LOVASTATIN (MEVINOLIN) IN THE TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - A MULTICENTER STUDY [J].

HAVEL, RJ ;

HUNNINGHAKE, DB ;

ILLINGWORTH, DR ;

LEES, RS ;

STEIN, EA ;

TOBERT, JA ;

BACON, SR ;

BOLOGNESE, JA ;

FROST, PH ;

LAMKIN, GE ;

LEES, AM ;

LEON, AS ;

GARDNER, K ;

JOHNSON, G ;

MELLIES, MJ ;

RHYMER, PA ;

TUN, P .

ANNALS OF INTERNAL MEDICINE, 1987, 107 (05) :609-615

[8]

KALES A, 1989, OCT WORLD C PSYCH AS

[9] PRECLINICAL EVALUATION OF LOVASTATIN [J].

MACDONALD, JS ;

GERSON, RJ ;

KORNBRUST, DJ ;

KLOSS, MW ;

PRAHALADA, S ;

BERRY, PH ;

ALBERTS, AW ;

BOKELMAN, DL .

AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (15) :J16-J27

[10]

MOSLEY ST, 1989, J LIPID RES, V30, P1411

← 1 2 3 →